Pharscin Pharma(SZ:002907)2025-06-26 07:14Group 1: Company Performance and Product Development - The five key traditional Chinese medicine products have seen a revenue increase of 24.49% year-on-year in Q1 2025, with the total revenue for these products growing by 31.44% year-to-date [3][4] - The sales of Gan Zhi Bing Mei Pian increased by 38.84% during the reporting period, with a year-to-date growth of 54.36% [3] - The company has received national-level protection for two key products, extending their protection period by 7 years [2] Group 2: Market Strategy and Sales Channels - Approximately 70% of the company's sales occur within public hospitals, with ongoing efforts to expand into grassroots hospitals, private hospitals, retail pharmacies, and e-commerce platforms [4] - The company is actively developing its presence in the retail pharmacy sector and e-commerce to increase its market share outside of hospitals [4] Group 3: Research and Development - The company has integrated its R&D capabilities with Chengdu Aorui Pharmaceutical Co., gaining control over 7 innovative drug projects targeting various cancers and autoimmune diseases [5][6] - R&D expenditures decreased by 44.58% in 2024 compared to the previous year, primarily due to a reduction in capitalized project amounts [8][9] Group 4: International Expansion - The company has achieved significant milestones in international markets, including obtaining FDA approval for its production base and registering key products in Singapore [10] - The successful registration of products in Singapore marks a critical step in the company's strategy to expand its overseas product offerings [10] Group 5: Response to Market Challenges - The company is adapting to price reductions from centralized procurement by diversifying its product lines and enhancing its marketing strategies [11] - The focus remains on leveraging existing sales channels while exploring new growth opportunities in specialty foods and nutritional products [11]